FDA Drug Approval Process: A Step-by-Step Guide

Introduction

The United States Food and Drug Administration (FDA) is responsible for ensuring that drugs marketed in the United States are safe and effective. The FDA drug approval process is one of the most rigorous regulatory frameworks in the world, designed to protect public health while facilitating the development of innovative therapies. Understanding this process is essential for pharmaceutical companies, researchers, healthcare professionals, and patients who want to comprehend how new medicines reach the market.

The journey from initial discovery to FDA approval typically spans 10–15 years and involves extensive pre-clinical research, multiple phases of clinical trials, and comprehensive regulatory review. This guide provides a detailed walkthrough of each stage of the FDA drug approval process, including the various application types, expedited pathways, and post-marketing requirements. For the latest regulatory news and drug approval announcements, visit the CodeDrug news section.

Pre-Clinical Research

Discovery and Development

The drug development process begins with discovery, where researchers identify potential therapeutic compounds through various approaches, including target-based drug discovery, phenotypic screening, and computational design. Thousands of compounds may be screened, with only a small fraction advancing to pre-clinical testing.

Pre-Clinical Studies

Before testing in humans, drug candidates undergo extensive laboratory and animal testing:

• Pharmacology studies: Characterize the mechanism of action, dose-response relationships, and pharmacokinetics
• Toxicology studies: Assess acute, sub-chronic, and chronic toxicity in at least two animal species (one rodent and one non-rodent)
• Reproductive toxicology: Evaluate effects on fertility, embryonic development, and postnatal development
• Genotoxicity testing: Assess mutagenic and clastogenic potential using bacterial and mammalian cell assays
• Safety pharmacology: Evaluate effects on vital organ systems (cardiovascular, respiratory, central nervous system)

Good Laboratory Practice (GLP)

Pre-clinical safety studies must be conducted in compliance with Good Laboratory Practice (GLP) regulations, which ensure the quality, integrity, and reliability of study data. GLP requirements cover study protocol design, personnel qualifications, facility standards, equipment calibration, and documentation.

Investigational New Drug (IND) Application

Purpose and Timing

Before initiating clinical trials in the United States, a sponsor must submit an Investigational New Drug (IND) application to the FDA. The IND application provides the data necessary for the FDA to determine whether the proposed clinical trials are safe to proceed.

IND Application Components

A complete IND application includes:

1. Pre-clinical data: Summaries of animal pharmacology and toxicology studies supporting the safety of human testing
2. Manufacturing information (CMC): Chemistry, Manufacturing, and Controls data describing the drug substance, drug product, manufacturing process, and analytical methods
3. Clinical protocol: Detailed description of the proposed Phase I trial, including study design, inclusion/exclusion criteria, safety monitoring, and statistical considerations
4. Investigator information: Qualifications of clinical investigators and institutional review board (IRB) approvals
5. Informed consent forms: Templates for patient informed consent

The 30-Day Review Period

Upon receiving an IND application, the FDA has 30 calendar days to review the submission. During this period:

• If the FDA has no concerns, the sponsor may begin clinical trials after the 30-day period
• If the FDA identifies safety concerns, it may issue a clinical hold, preventing the trial from starting until the issues are resolved
• The sponsor and FDA typically communicate during the review period to address any questions

Types of INDs

• Commercial IND: Submitted by pharmaceutical companies for drug development leading to marketing approval
• Research/Investigator IND: Submitted by physician-investigators studying an unapproved drug or an approved drug for a new indication
• Emergency Use IND: Allows use of an investigational drug in emergency situations for patients who do not meet existing trial criteria
• Treatment IND: For experimental drugs showing promise in clinical testing for serious or life-threatening conditions

Clinical Development Phases

Clinical development follows a structured phased approach, as detailed in our clinical trial phases guide. A brief summary:

Phase I

• Participants: 20–100 healthy volunteers (or patients for oncology drugs)
• Objective: Safety, tolerability, pharmacokinetics
• Duration: Several months

Phase II

• Participants: 100–300 patients with the target disease
• Objective: Preliminary efficacy, dose optimization, continued safety evaluation
• Duration: 1–3 years

Phase III

• Participants: 300–3,000+ patients across multiple sites
• Objective: Definitive efficacy and safety, comparison with standard therapy
• Duration: 2–5 years

Approximately 25–30% of drugs entering Phase I eventually receive FDA approval.

New Drug Application (NDA) and Biologics License Application (BLA)

Purpose

After successful completion of clinical trials, the sponsor submits either a New Drug Application (NDA) for small molecule drugs or a Biologics License Application (BLA) for biologics. These comprehensive applications provide the FDA with all the data needed to determine whether a drug is safe and effective for its intended use.

Application Components

An NDA/BLA typically includes:

• Pre-clinical data: Full reports of all animal studies
• Clinical data: Individual patient data and integrated summaries of efficacy and safety from all clinical trials
• CMC information: Detailed manufacturing process, controls, and stability data
• Proposed labeling: Package insert with indications, dosing, warnings, and adverse reactions
• Risk evaluation and mitigation strategy (REMS): If required, strategies to ensure benefits outweigh risks

Common Technical Document (CTD) Format

NDAs and BLAs are organized according to the International Council for Harmonisation (ICH) Common Technical Document format, which standardizes the structure across major regulatory jurisdictions:

• Module 1: Administrative information (region-specific)
• Module 2: Quality, non-clinical, and clinical summaries
• Module 3: Quality (CMC) data
• Module 4: Non-clinical study reports
• Module 5: Clinical study reports

FDA Review Process

Filing Review (60 days)

The FDA first determines whether the application is sufficiently complete to file (accept for review). If the application is incomplete, the FDA issues a Refuse to File (RTF) letter.

Substantive Review (6–10 months)

For standard reviews, the FDA has 10 months to complete review; for priority reviews, 6 months. The review involves:

• Multi-disciplinary review: Teams of medical officers, chemists, statisticians, pharmacologists, and other specialists review relevant sections
• Advisory committee meetings: For novel drugs or controversial decisions, the FDA convenes independent expert advisory committees for recommendations
• Labeling negotiations: FDA and sponsor negotiate the final product labeling
• Facility inspections: Pre-approval inspections of manufacturing facilities to verify GMP compliance

Approval Decision

The FDA’s decision options include:

• Approval: Drug is approved for marketing with agreed-upon labeling
• Complete Response Letter (CRL): Identifies deficiencies that must be addressed before approval; the sponsor can resubmit with additional data
• Approval with post-marketing requirements: Approval contingent on additional studies or safety monitoring

Expedited Review Pathways

The FDA has established several programs to accelerate the development and review of drugs for serious conditions with unmet medical needs:

Fast Track Designation

• Designed for drugs treating serious conditions with unmet medical needs
• Enables rolling review (portions of the NDA submitted as completed)
• More frequent FDA interactions and guidance
• Does not inherently shorten review time but improves development efficiency

Breakthrough Therapy Designation

• For drugs demonstrating substantial improvement over existing therapies on clinically significant endpoints
• All Fast Track features plus intensive FDA guidance beginning in Phase I or II
• Senior FDA managers assigned to facilitate development
• More frequent communication and organizational commitment to expedited development

Accelerated Approval

• Allows approval based on surrogate endpoints reasonably likely to predict clinical benefit
• Requires post-marketing confirmatory trials to verify clinical benefit
• Common in oncology (tumor response rate) and rare diseases
• The FDA may withdraw approval if confirmatory trials fail to verify benefit

Priority Review

• 6-month review target (vs. 10 months standard)
• For drugs that would represent significant improvements in safety or effectiveness
• Can be combined with other expedited pathways

Regenerative Medicine Advanced Therapy (RMAT) Designation

• For regenerative medicine therapies (cell therapy, therapeutic tissue engineering, combination products)
• Includes all Breakthrough Therapy benefits plus potential for expedited development

Post-Marketing Surveillance

Phase IV Studies

Post-marketing (Phase IV) studies may be required or requested to:

• Monitor long-term safety in larger, more diverse populations
• Evaluate efficacy in specific subpopulations (pediatric, elderly, pregnancy)
• Assess outcomes with concomitant medications (see drug-drug interaction analysis)
• Compare with other approved therapies

Adverse Event Reporting

• MedWatch: FDA’s adverse event reporting system for healthcare professionals and consumers
• Mandatory reporting: Sponsors must report serious, unexpected adverse events within 15 days
• Periodic safety reports: Regular submission of aggregate safety data
• REMS: Risk Evaluation and Mitigation Strategies for drugs with significant safety concerns

Post-Marketing Actions

The FDA can take several post-marketing actions:

• Label changes: Adding warnings, contraindications, or new indications
• Safety communications: Alerts to healthcare professionals and the public
• Boxed warnings: The strongest warning level for serious risks
• Market withdrawal: Removing a drug from the market if risks outweigh benefits

Special Considerations

Orphan Drug Designation

For drugs treating rare diseases (affecting fewer than 200,000 people in the US), orphan drug designation provides:

• Seven years of market exclusivity upon approval
• Tax credits for clinical development costs
• FDA grant funding for clinical trials
• Waiver of PDUFA filing fees

Generic Drug Approval (ANDA)

Generic drugs are approved through Abbreviated New Drug Applications (ANDAs), which must demonstrate:

• Bioequivalence to the reference listed drug
• Same active ingredient, dosage form, strength, route of administration, and labeling
• No need to repeat pre-clinical or clinical efficacy studies

Biosimilar Approval

Biosimilars—biologic products highly similar to an approved reference product—follow a distinct pathway under the Biologics Price Competition and Innovation Act, requiring comparative analytical, clinical, and immunogenicity studies. This process is described further in our comparison of biologics and small molecule drugs.

Conclusion

The FDA drug approval process represents a carefully balanced framework that protects public health while encouraging pharmaceutical innovation. From the initial IND application through post-marketing surveillance, each stage serves a critical function in ensuring that new medicines are safe, effective, and properly labeled. The various expedited pathways—for breakthrough therapies, accelerated approvals, and priority reviews—enable faster access to promising treatments for patients with serious conditions while maintaining rigorous safety standards. Understanding this process is essential for all stakeholders in the pharmaceutical ecosystem. For researchers and clinicians seeking detailed drug information and regulatory data, the CodeDrug database and research tools provide comprehensive resources to support regulatory compliance and informed clinical decision-making.